PolyPid PYPD 深 沪
等待开盘 07-22 09:30:00 美东时间
3.74
-1.410
-27.38%
华盛通- 最 高4.84
- 今 开4.79
- 成交量 221.96万股
- 最 低 3.72
- 昨 收 5.15
- 总市值 7171.11万
- 52周最高 5.73
- 市盈率 静 --
- 换手率 11.58%
- 52周最低 3.06
- 委 比 12.25%
- 总股本 1917.41万
- 历史最高 583.50
- 量 比 11.59
- 振 幅 21.75%
- 历史最低 2.30
- 每 手 1
- 风险率 0.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
28分钟前
PolyPid Signs Agreement With Azurity Pharmaceuticals To Commercialize D-PLEX100 In U.S., Canada To Prevent Surgical Site Infections; PolyPid To Receive $15M Upfront Payment
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that it has entered into an exclusive commercial partnership agreement (the "Agreement") with Azurity Pharmaceutic...
07-21 19:32
PolyPid Completes Its New Drug Application Submission On Rolling Review Basis Top FDA For D-PLEX100 To Prevent Surgical Site Infections
PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced the
06-01 20:40
PolyPid Q1 2026 Earnings Call: Complete Transcript
PolyPid (NASDAQ:PYPD) held its first-quarter earnings conference call on Wednes...
05-13 21:24
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026
PolyPid Ltd. (Nasdaq: PYPD) announced it will report its first quarter 2026 financial results and operational highlights on Wednesday, May 13, 2026, before the U.S. market open. A conference call and webcast at 8:30 AM Eastern Time will discuss the results and business updates. The company, focused on improving patient outcomes through innovative biopharmaceuticals, invites participants to register in advance for the call or listen via webcast.
05-06 12:00
PolyPid To Present ASEPSIS Analysis Data From Its Phase 3 SHIELD II Study Of D-PLEX At 5th Annual Meeting Of The Surgical Infection Society
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that
04-28 20:37
PolyPid To Present Phase 3 SHIELD II Data Showing Sustained Local Doxycycline Release And Minimal Systemic Exposure At ESCMID 2026 Conference
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that
04-13 21:16
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
PolyPid Ltd. has initiated the submission of its New Drug Application (NDA) to the FDA for D-PLEX₁₀₀, aimed at preventing surgical site infections (SSIs) in colorectal surgery patients. The submission, under the FDA’s Fast Track designation, includes the Chemistry, Manufacturing and Controls (CMC) and nonclinical sections, with the clinical section expected in the second quarter of 2026. D-PLEX₁₀₀, which uses PolyPid’s Kynatrix technology, provid...
03-31 12:30
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application
PolyPid Ltd. announced that the FDA has granted a $4.3 million small business waiver for its New Drug Application (NDA) for D-PLEX₁₀₀, aimed at preventing surgical site infections in abdominal colorectal surgeries. This waiver supports the company's commercialization efforts and enables it to focus on submitting the first sections of its rolling NDA by the end of this month. D-PLEX₁₀₀ demonstrated a 60% relative risk reduction in infections in th...
03-17 12:30
